1887

Abstract

Hantaan virus (HTNV), a member of the family , is a major agent causing haemorrhagic fever with renal syndrome, a high-mortality-rate disease threatening approximately 150 000 people around the world yearly. The 3D8 mAb displays a neutralizing activity to HTNV infection. In this study, the B-cell epitopes of HTNV glycoproteins (GPs) were finely mapped by peptide scanning. A new B-cell epitope GFLCPEFPGSFRKKC of HTNV, which locates on Gc, has been screened out from a set of 15-mer synthesized peptides covering the full-length of HTNV-GPs. It has been shown by the alanine-scanning technique that C, R, K, K and C are the key amino acids of the binding sites of the GPs. The implications of identifying a novel B-cell epitope for hantavirus immunology and vaccinology are discussed.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.045302-0
2012-12-01
2019-10-20
Loading full text...

Full text loading...

/deliver/fulltext/jgv/93/12/2595.html?itemId=/content/journal/jgv/10.1099/vir.0.045302-0&mimeType=html&fmt=ahah

References

  1. Antoniades A. , Grekas D. , Rossi C. A. , LeDuc J. W. . ( 1987; ). Isolation of a hantavirus from a severely ill patient with hemorrhagic fever with renal syndrome in Greece. . J Infect Dis 156:, 1010–1013. [CrossRef] [PubMed]
    [Google Scholar]
  2. Arikawa J. , Schmaljohn A. L. , Dalrymple J. M. , Schmaljohn C. S. . ( 1989; ). Characterization of Hantaan virus envelope glycoprotein antigenic determinants defined by monoclonal antibodies. . J Gen Virol 70:, 615–624. [CrossRef] [PubMed]
    [Google Scholar]
  3. Arikawa J. , Yao J. S. , Yoshimatsu K. , Takashima I. , Hashimoto N. . ( 1992; ). Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies. . Arch Virol 126:, 271–281. [CrossRef] [PubMed]
    [Google Scholar]
  4. Bui-Mansfield L. T. , Cressler D. K. . ( 2011; ). Imaging of hemorrhagic fever with renal syndrome: a potential bioterrorism agent of military significance. . Mil Med 176:, 1327–1334.[PubMed] [CrossRef]
    [Google Scholar]
  5. de Carvalho Nicacio C. , Lundkvist A. , Sjölander K. B. , Plyusnin A. , Salonen E. M. , Björling E. . ( 2000; ). A neutralizing recombinant human antibody Fab fragment against Puumala hantavirus. . J Med Virol 60:, 446–454. [CrossRef] [PubMed]
    [Google Scholar]
  6. Dowling W. , Thompson E. , Badger C. , Mellquist J. L. , Garrison A. R. , Smith J. M. , Paragas J. , Hogan R. J. , Schmaljohn C. . ( 2007; ). Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of Ebola virus GP DNA vaccines. . J Virol 81:, 1821–1837. [CrossRef] [PubMed]
    [Google Scholar]
  7. Gnann J. W. Jr , Nelson J. A. , Oldstone M. B. . ( 1987; ). Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. . J Virol 61:, 2639–2641.[PubMed]
    [Google Scholar]
  8. Huggins J. W. , Hsiang C. M. , Cosgriff T. M. , Guang M. Y. , Smith J. I. , Wu Z. O. , LeDuc J. W. , Zheng Z. M. , Meegan J. M. . & other authors ( 1991; ). Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. . J Infect Dis 164:, 1119–1127. [CrossRef] [PubMed]
    [Google Scholar]
  9. Jonsson C. B. , Figueiredo L. T. , Vapalahti O. . ( 2010; ). A global perspective on hantavirus ecology, epidemiology, and disease. . Clin Microbiol Rev 23:, 412–441. [CrossRef] [PubMed]
    [Google Scholar]
  10. Kikuchi M. , Yoshimatsu K. , Arikawa J. , Yoshida R. , Yoo Y. C. , Isegawa Y. , Yamanishi K. , Tono-oka S. , Azuma I. . ( 1998; ). Characterization of neutralizing monoclonal antibody escape mutants of Hantaan virus 76118. . Arch Virol 143:, 73–83. [CrossRef] [PubMed]
    [Google Scholar]
  11. Koch J. , Liang M. , Queitsch I. , Kraus A. A. , Bautz E. K. . ( 2003; ). Human recombinant neutralizing antibodies against Hantaan virus G2 protein. . Virology 308:, 64–73. [CrossRef] [PubMed]
    [Google Scholar]
  12. Koivunen E. , Gay D. A. , Ruoslahti E. . ( 1993; ). Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. . J Biol Chem 268:, 20205–20210.[PubMed]
    [Google Scholar]
  13. Koivunen E. , Wang B. , Ruoslahti E. . ( 1994; ). Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. . J Cell Biol 124:, 373–380. [CrossRef] [PubMed]
    [Google Scholar]
  14. Liang M. , Mahler M. , Koch J. , Ji Y. , Li D. , Schmaljohn C. , Bautz E. K. . ( 2003; ). Generation of an HFRS patient-derived neutralizing recombinant antibody to Hantaan virus G1 protein and definition of the neutralizing domain. . J Med Virol 69:, 99–107. [CrossRef] [PubMed]
    [Google Scholar]
  15. X. , Yin W. , Yang Q. , Lei Y. , Yang J. , Sun M. , Yao M. , Xu Z. , Xue X. . ( 2009; ). Identification of oligopeptides mimicking the receptor-binding domain of Hantaan virus envelope glycoprotein from a phage-displayed peptide library. . Can J Microbiol 55:, 664–671. [CrossRef] [PubMed]
    [Google Scholar]
  16. Lundkvist A. , Björsten S. , Niklasson B. , Ahlborg N. . ( 1995; ). Mapping of B-cell determinants in the nucleocapsid protein of Puumala virus: definition of epitopes specific for acute immunoglobulin G recognition in humans. . Clin Diagn Lab Immunol 2:, 82–86.[PubMed]
    [Google Scholar]
  17. McCaughey C. , Hart C. A. . ( 2000; ). Hantaviruses. . J Med Microbiol 49:, 587–599.[PubMed]
    [Google Scholar]
  18. Peters C. J. , Simpson G. L. , Levy H. . ( 1999; ). Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. . Annu Rev Med 50:, 531–545. [CrossRef] [PubMed]
    [Google Scholar]
  19. Rusnak J. M. , Byrne W. R. , Chung K. N. , Gibbs P. H. , Kim T. T. , Boudreau E. F. , Cosgriff T. , Pittman P. , Kim K. Y. . & other authors ( 2009; ). Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea. . Antiviral Res 81:, 68–76. [CrossRef] [PubMed]
    [Google Scholar]
  20. Safronetz D. , Haddock E. , Feldmann F. , Ebihara H. , Feldmann H. . ( 2011; ). In vitro and in vivo activity of ribavirin against Andes virus infection. . PLoS ONE 6:, e23560. [CrossRef] [PubMed]
    [Google Scholar]
  21. Tischler N. D. , Galeno H. , Rosemblatt M. , Valenzuela P. D. . ( 2005; ). Human and rodent humoral immune responses to Andes virus structural proteins. . Virology 334:, 319–326. [CrossRef] [PubMed]
    [Google Scholar]
  22. Xu Z. . ( 2011; ). Research and applications of monoclonal antibodies in viral disease therapy. . Chin J Viral Dis 1:, 401–404.
    [Google Scholar]
  23. Xu Z. , Wei L. , Wang L. , Wang H. , Jiang S. . ( 2002; ). The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunization. . Biochem Biophys Res Commun 298:, 552–558. [CrossRef] [PubMed]
    [Google Scholar]
  24. Xu R. , Yang X. Y. , Yang D. F. , Zou C. Y. , Gong P. L. , Zeng F. D. . ( 2009; ). Phase I evaluation of the safety and pharmacokinetics of a single-dose intravenous injection of a murine monoclonal antibody against Hantaan virus in healthy volunteers. . Antimicrob Agents Chemother 53:, 5055–5059. [CrossRef] [PubMed]
    [Google Scholar]
  25. Yoshimatsu K. , Arikawa J. , Tamura M. , Yoshida R. , Lundkvist A. , Niklasson B. , Kariwa H. , Azuma I. . ( 1996; ). Characterization of the nucleocapsid protein of Hantaan virus strain 76-118 using monoclonal antibodies. . J Gen Virol 77:, 695–704. [CrossRef] [PubMed]
    [Google Scholar]
  26. Zhu Z. , Dimitrov A. S. , Chakraborti S. , Dimitrova D. , Xiao X. , Broder C. C. , Dimitrov D. S. . ( 2006; ). Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses. . Expert Rev Anti Infect Ther 4:, 57–66. [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.045302-0
Loading
/content/journal/jgv/10.1099/vir.0.045302-0
Loading

Data & Media loading...

Supplements

Supplementary table 

PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error